BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23554843)

  • 21. Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.
    Rubenstein M; Hollowell CM; Guinan P
    In Vivo; 2011; 25(1):61-7. PubMed ID: 21282736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2007; 24(2):189-96. PubMed ID: 17848743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
    Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
    Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.
    Rubenstein M; Hollowell CM; Guinan P
    Med Oncol; 2010 Dec; 27(4):1212-8. PubMed ID: 19937163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line.
    Chang HC; Chen SC; Chen J; Hsieh JT
    J Formos Med Assoc; 2005 Sep; 104(9):652-8. PubMed ID: 16276440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2008; 25(2):182-6. PubMed ID: 17972023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen deprivation increases p300 expression in prostate cancer cells.
    Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
    Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-4 activates androgen receptor through CBP/p300.
    Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
    Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
    Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
    Rubenstein M; Anderson KM; Tsui P; Guinan P
    Med Hypotheses; 2006; 67(6):1375-80. PubMed ID: 16870352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.
    Udayakumar TS; Hachem P; Ahmed MM; Agrawal S; Pollack A
    Mol Cancer Res; 2008 Nov; 6(11):1742-54. PubMed ID: 19010821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.
    Boorjian SA; Heemers HV; Frank I; Farmer SA; Schmidt LJ; Sebo TJ; Tindall DJ
    Endocr Relat Cancer; 2009 Mar; 16(1):123-37. PubMed ID: 18845648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
    Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
    Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):649-52. PubMed ID: 12616956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
    Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H
    Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2007; 24(4):372-8. PubMed ID: 17917084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.